Arcutis Biotherapeutics, Inc.
ARQTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The $3.92B market capitalization puts ARQT squarely in mid-cap range for its industry. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Market Cap
$3.92B
Beta
1.58
P/E (TTM)
141.82
P/E (Fwd)
23.31
EPS (TTM)
$0.22
EPS (Fwd)
$1.34
ROE
15.9%
ROA
5.1%
Cash
$238.6M
Total Debt
$114.1M
Free CF
$21.7M
52W Change
58.9%
Annual Financials
Cash vs Debt
Where ARQT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARQT finished 29.06% above its 150-day moving average ($24.71) and 27.10% above its 200-day moving average ($25.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARQT overbought or oversold?
At the October 20, 2026 close, ARQT's RSI(14) was 70.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $238.6M in cash comfortably exceeding the $114.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $21.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 15.9% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $3.7M (2022) to $376.1M (2025), reflecting a 10103% increase over the period.
Arcutis Biotherapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ARQT has financial flexibility that may help navigate uncertain periods. At over 50x earnings, ARQT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arcutis Biotherapeutics, Inc. and its sector.